Koji Ando1, Yasunori Emi2, Toyokuni Suenaga3, Masahiro Hamanoue4, Soichiro Maekawa5, Yasuo Sakamoto6, Seiichiro Kai7, Hironaga Satake8, Takayuki Shimose9, Mototsugu Shimokawa10, Hiroshi Saeki1, Eiji Oki11, Kenji Sakai12, Yoshito Akagi13, Hideo Baba14, Yoshihiko Maehara1. 1. Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. 2. Department of Surgery, Saiseikai Fukuoka General Hospital, Fukuoka, Japan. 3. Surgery/Gastrointestinal Surgery, Public Interest Incorporated Association, Kagoshima, Nanpuh Hospital, Kagoshima, Japan. 4. Department of Surgery, Imakiire General Hospital, Kagoshima, Japan. 5. Department of Surgery, Munakata Medical Association Hospital, Fukuoka, Japan. 6. Department of Gastroenterological Surgery, Kumamoto University Hospital, Kumamoto, Japan. 7. Department of Surgery, Nakatsu Municipal Hospital, Oita, Japan. 8. Department of Medical Oncology, Kobe City Medical Center General Hospital, Kobe, Japan. 9. Clinical Research Support Center Kyushu, Fukuoka, Japan. 10. Department of Cancer Information Research, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan. 11. Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. okieiji@surg2.med.kyushu-u.ac.jp. 12. Department of Medical Oncology, National Hospital Organization Kumamoto Medical Center, Kumamoto, Japan. 13. Department of Surgery, School of Medicine, Kurume University, Fukuoka, Japan. 14. Department of Gastroenterological Surgery, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.
Abstract
BACKGROUND: This study was designed to evaluate the efficacy and toxicity of XELIRI plus bevacizumab for the treatment of Japanese patients with unresectable or recurrent colorectal cancer (CRC). METHODS: This was a multicenter, single-arm, open-label prospective study. The major inclusion criteria were previously untreated unresectable or recurrent CRC, presence of measurable lesions, ≥20 years of age, Eastern Cooperative Oncology Group performance status 0 or 1, and adequate organ function. Patients received bevacizumab (7.5 mg/kg on day 1) and XELIRI (irinotecan 200 mg/m2 on day 1 plus capecitabine 800 mg/m2 b.i.d. on days 1-14) every 3 weeks. The primary endpoint was the objective tumor response rate. RESULTS: A total of 36 patients were enrolled in this study from July 2011 to September 2012. One patient did not fulfill the eligibility criteria and one patient withdrew their consent before the start of the treatment protocol. The confirmed objective response rate was 58.8% (95% CI 35.1-70.2%). The median progression-free survival was 9.6 months (95% CI 5.1-11.1 months) and the median overall survival was 23.1 months (95% CI 11.3-36.7 months). The grade ≥3 adverse events that were frequently encountered in this study were neutropenia (31.4%), leukopenia (22.9%), diarrhea (22.9%), anemia (20.0%), anorexia (20.0%) and febrile neutropenia (17.2%). The frequency of grade 3/4 adverse events, such as neutropenia and leukopenia, was much higher in patients with a UGT1A1 polymorphism. CONCLUSIONS: A first-line therapy comprising XELIRI plus bevacizumab yielded a promising response rate. However, careful attention should be given to adverse clinical events in Japanese patients receiving treatment with unresectable or recurrent CRC.
BACKGROUND: This study was designed to evaluate the efficacy and toxicity of XELIRI plus bevacizumab for the treatment of Japanese patients with unresectable or recurrent colorectal cancer (CRC). METHODS: This was a multicenter, single-arm, open-label prospective study. The major inclusion criteria were previously untreated unresectable or recurrent CRC, presence of measurable lesions, ≥20 years of age, Eastern Cooperative Oncology Group performance status 0 or 1, and adequate organ function. Patients received bevacizumab (7.5 mg/kg on day 1) and XELIRI (irinotecan 200 mg/m2 on day 1 plus capecitabine 800 mg/m2 b.i.d. on days 1-14) every 3 weeks. The primary endpoint was the objective tumor response rate. RESULTS: A total of 36 patients were enrolled in this study from July 2011 to September 2012. One patient did not fulfill the eligibility criteria and one patient withdrew their consent before the start of the treatment protocol. The confirmed objective response rate was 58.8% (95% CI 35.1-70.2%). The median progression-free survival was 9.6 months (95% CI 5.1-11.1 months) and the median overall survival was 23.1 months (95% CI 11.3-36.7 months). The grade ≥3 adverse events that were frequently encountered in this study were neutropenia (31.4%), leukopenia (22.9%), diarrhea (22.9%), anemia (20.0%), anorexia (20.0%) and febrile neutropenia (17.2%). The frequency of grade 3/4 adverse events, such as neutropenia and leukopenia, was much higher in patients with a UGT1A1 polymorphism. CONCLUSIONS: A first-line therapy comprising XELIRI plus bevacizumab yielded a promising response rate. However, careful attention should be given to adverse clinical events in Japanese patients receiving treatment with unresectable or recurrent CRC.
Authors: P M Hoff; R Ansari; G Batist; J Cox; W Kocha; M Kuperminc; J Maroun; D Walde; C Weaver; E Harrison; H U Burger; B Osterwalder; A O Wong; R Wong Journal: J Clin Oncol Date: 2001-04-15 Impact factor: 44.544
Authors: E Van Cutsem; C Twelves; J Cassidy; D Allman; E Bajetta; M Boyer; R Bugat; M Findlay; S Frings; M Jahn; J McKendrick; B Osterwalder; G Perez-Manga; R Rosso; P Rougier; W H Schmiegel; J F Seitz; P Thompson; J M Vieitez; C Weitzel; P Harper Journal: J Clin Oncol Date: 2001-11-01 Impact factor: 44.544
Authors: M M Borner; J Bernhard; D Dietrich; R Popescu; M Wernli; P Saletti; D Rauch; R Herrmann; D Koeberle; H Honegger; P Brauchli; D Lanz; A D Roth Journal: Ann Oncol Date: 2005-02 Impact factor: 32.976
Authors: D W Rea; J W R Nortier; W W Ten Bokkel Huinink; S Falk; D J Richel; T Maughan; G Groenewegen; J M Smit; N Steven; J M Bakker; D Semiond; D J Kerr; C J A Punt Journal: Ann Oncol Date: 2005-06-06 Impact factor: 32.976
Authors: M Ducreux; A Adenis; J-P Pignon; E François; B Chauffert; J L Ichanté; E Boucher; M Ychou; J-Y Pierga; C Montoto-Grillot; T Conroy Journal: Eur J Cancer Date: 2013-01-24 Impact factor: 9.162
Authors: W Schmiegel; A Reinacher-Schick; D Arnold; S Kubicka; W Freier; G Dietrich; M Geißler; S Hegewisch-Becker; A Tannapfel; M Pohl; A Hinke; H J Schmoll; U Graeven Journal: Ann Oncol Date: 2013-03-04 Impact factor: 32.976